Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

Ado-trastuzumab Emtansine is used to treat HER2-positive metastatic breast cancer, a specific type of breast cancer that has moved to other parts of the body. The risk or severity of adverse ...

More information: Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer, New England Journal of Medicine (2025). DOI: 10.1056/NEJMoa2406070 Provided by University of Pittsburgh ...